| __timestamp | Eli Lilly and Company | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6620800000 | 72471000 |
| Thursday, January 1, 2015 | 6533000000 | 89204000 |
| Friday, January 1, 2016 | 6452000000 | 106010000 |
| Sunday, January 1, 2017 | 6588100000 | 137905000 |
| Monday, January 1, 2018 | 5975100000 | 159888000 |
| Tuesday, January 1, 2019 | 6213800000 | 158425000 |
| Wednesday, January 1, 2020 | 6121200000 | 200677000 |
| Friday, January 1, 2021 | 6431600000 | 304759000 |
| Saturday, January 1, 2022 | 6440400000 | 377221000 |
| Sunday, January 1, 2023 | 6941200000 | 336361000 |
| Monday, January 1, 2024 | 8593800000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, understanding the financial strategies of industry leaders is crucial. Over the past decade, Eli Lilly and Company and Supernus Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Eli Lilly's SG&A expenses have seen a steady increase, peaking in 2023 with a 5% rise from the previous year. This reflects their aggressive market expansion and investment in administrative capabilities. In contrast, Supernus Pharmaceuticals, while smaller in scale, has demonstrated a remarkable growth trajectory, with SG&A expenses increasing by over 360% from 2014 to 2023. This surge underscores their strategic focus on scaling operations and enhancing market presence. These trends highlight the differing strategies of a pharmaceutical giant and a rising contender, offering insights into their operational priorities and market positioning.
Eli Lilly and Company or Gilead Sciences, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Incyte Corporation
Selling, General, and Administrative Costs: Eli Lilly and Company vs Pharming Group N.V.
Operational Costs Compared: SG&A Analysis of Eli Lilly and Company and Axsome Therapeutics, Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Merus N.V. Trends and Insights
SG&A Efficiency Analysis: Comparing Eli Lilly and Company and Vericel Corporation
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Axsome Therapeutics, Inc. or Supernus Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Supernus Pharmaceuticals, Inc.